AT348115B - Verfahren zur umwandlung eines anti- inflammatorisch wirkenden steroids - Google Patents

Verfahren zur umwandlung eines anti- inflammatorisch wirkenden steroids

Info

Publication number
AT348115B
AT348115B AT352973A AT352973A AT348115B AT 348115 B AT348115 B AT 348115B AT 352973 A AT352973 A AT 352973A AT 352973 A AT352973 A AT 352973A AT 348115 B AT348115 B AT 348115B
Authority
AT
Austria
Prior art keywords
converting
inflammatory steroid
steroid
inflammatory
Prior art date
Application number
AT352973A
Other languages
English (en)
Other versions
ATA352973A (de
Original Assignee
Allen & Hanburys Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10112152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AT348115(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allen & Hanburys Ltd filed Critical Allen & Hanburys Ltd
Publication of ATA352973A publication Critical patent/ATA352973A/de
Application granted granted Critical
Publication of AT348115B publication Critical patent/AT348115B/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT352973A 1972-04-20 1973-04-19 Verfahren zur umwandlung eines anti- inflammatorisch wirkenden steroids AT348115B (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1842172A GB1429184A (en) 1972-04-20 1972-04-20 Physically anti-inflammatory steroids for use in aerosols

Publications (2)

Publication Number Publication Date
ATA352973A ATA352973A (de) 1978-06-15
AT348115B true AT348115B (de) 1979-01-25

Family

ID=10112152

Family Applications (1)

Application Number Title Priority Date Filing Date
AT352973A AT348115B (de) 1972-04-20 1973-04-19 Verfahren zur umwandlung eines anti- inflammatorisch wirkenden steroids

Country Status (23)

Country Link
US (2) US4414209A (de)
JP (1) JPS531814B2 (de)
AR (1) AR196524A1 (de)
AT (1) AT348115B (de)
AU (1) AU471577B2 (de)
BE (1) BE798458A (de)
CA (1) CA994753A (de)
DE (1) DE2320111C2 (de)
DK (1) DK134923B (de)
ES (1) ES413911A1 (de)
FI (1) FI53067C (de)
FR (1) FR2182981B1 (de)
GB (1) GB1429184A (de)
HU (1) HU171209B (de)
IE (1) IE37541B1 (de)
IL (1) IL42038A (de)
LU (1) LU67462A1 (de)
NL (1) NL157797B (de)
NO (1) NO140303C (de)
PH (1) PH13620A (de)
SE (1) SE399642B (de)
YU (1) YU39602B (de)
ZA (1) ZA732713B (de)

Families Citing this family (323)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX3864E (es) * 1975-05-27 1981-08-26 Syntex Corp Un proceso para prepara el compuesto cristalino 6-fluiro-11b 21-dihiroxi-16 17-isopropilidendioxipregna-1 4-dien-3 20-diona
US4933168A (en) * 1975-05-27 1990-06-12 Syntex Pharmaceuticals International Limited Stable, crystalline flunisolide
GB1571629A (en) * 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
IT1121513B (it) * 1979-05-28 1986-04-02 Chiesi Farma Spa Processo per la conversione di umo steroide antiinfiammatorio in una forma suscettibile di essere somministarta come aerosol
EP0039369B1 (de) * 1980-05-02 1983-06-15 Schering Corporation Beclomethason-ester-solvate, Verfahren zu ihrer Herstellung und Herstellung einer Formulierung
FI63672C (fi) * 1980-05-19 1983-08-10 Orion Yhtymae Oy Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan
KR890000664B1 (ko) * 1981-10-19 1989-03-22 바리 안소니 뉴우샘 미분된 베클로메타손 디프로피오네이트 일수화물의 제조방법
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
US5962490A (en) * 1987-09-25 1999-10-05 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5562608A (en) * 1989-08-28 1996-10-08 Biopulmonics, Inc. Apparatus for pulmonary delivery of drugs with simultaneous liquid lavage and ventilation
US5736509A (en) * 1990-12-14 1998-04-07 Texas Biotechnology Corporation Cyclic peptide surface feature mimics of endothelin
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5916540A (en) 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
ES2123576T3 (es) 1991-12-12 1999-01-16 Glaxo Group Ltd Medicamentos.
US5683676A (en) * 1991-12-12 1997-11-04 Glaxo Group Limited Canister containing aerosol formulations containing P134a and particulate medicaments
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
IL104068A (en) 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
US5301664A (en) * 1992-03-06 1994-04-12 Sievers Robert E Methods and apparatus for drug delivery using supercritical solutions
AU659328B2 (en) * 1992-06-12 1995-05-11 Teijin Limited Ultrafine powder for inhalation and production thereof
MX9304585A (es) 1992-07-31 1994-03-31 Glaxo Group Ltd Formulacion farmaceutica en aerosol, lata adecuada para liberar la formulacion e inhalador de dosis dosificada que comprende la lata.
WO1994022427A1 (en) * 1993-04-01 1994-10-13 Amgen Inc. Method for preparing drugs to treat dermal disorders
US6030991A (en) * 1993-05-20 2000-02-29 Texas Biotechnology Corp. Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6613804B2 (en) 1993-05-20 2003-09-02 Encysive Pharmaceuticals, Inc. Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US6376523B1 (en) 1994-05-20 2002-04-23 Texas Biotechnology Corporation Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6541498B2 (en) 1993-05-20 2003-04-01 Texas Biotechnology Benzenesulfonamides and the use thereof to modulate the activity of endothelin
US6342610B2 (en) 1993-05-20 2002-01-29 Texas Biotechnology Corp. N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US6551618B2 (en) 1994-03-15 2003-04-22 University Of Birmingham Compositions and methods for delivery of agents for neuronal regeneration and survival
AU693590B2 (en) * 1994-08-09 1998-07-02 Schering Corporation Process for preparing beclomethasone dipropionate freon (R) clathrate
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US6017887A (en) * 1995-01-06 2000-01-25 Sibia Neurosciences, Inc. Peptide, peptide analog and amino acid analog protease inhibitors
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5646130A (en) * 1995-06-30 1997-07-08 Ocean University Of Oingdao Low molecular weight sulfated polysaccharides and uses thereof
US5977117A (en) * 1996-01-05 1999-11-02 Texas Biotechnology Corporation Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5700487A (en) * 1996-03-04 1997-12-23 The Ohio State University Treatment of pulmonary inflammation
US5958905A (en) 1996-03-26 1999-09-28 Texas Biotechnology Corporation Phosphoramidates, phosphinic amides and related compounds and the use thereof to modulate the activity of endothelin
US5804585A (en) * 1996-04-15 1998-09-08 Texas Biotechnology Corporation Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin
CA2252617A1 (en) * 1996-05-01 1997-11-06 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6416960B1 (en) 1996-08-08 2002-07-09 Prolume, Ltd. Detection and visualization of neoplastic tissues and other tissues
SE9603725D0 (sv) * 1996-10-11 1996-10-11 Astra Ab New teatment
US6380222B2 (en) 1996-10-11 2002-04-30 Astrazeneca Ab Use of an H+, K+-atpase inhibitor in the treatment of nasal polyps
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
SE9700133D0 (sv) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
US5783705A (en) 1997-04-28 1998-07-21 Texas Biotechnology Corporation Process of preparing alkali metal salys of hydrophobic sulfonamides
CA2496680A1 (en) 1997-04-28 1998-11-05 Encysive Pharmaceuticals Inc. Sulfonamide compounds and salts for treatment of endothelin-mediated disorders
US6342611B1 (en) * 1997-10-10 2002-01-29 Cytovia, Inc. Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof
US6362009B1 (en) 1997-11-21 2002-03-26 Merck & Co., Inc. Solid phase synthesis of heterocycles
WO1999040771A2 (en) 1998-02-13 1999-08-19 Selective Genetics, Inc. Concurrent flow mixing for preparing compositions comprising gene therapy vectors
EP1925320A3 (de) 1998-03-27 2008-09-03 Prolume, Ltd. Luciferasen, fluoreszierende Proteine, Nukleinsäuren zur Kodierung der Luciferasen und der fluoreszierenden Proteine sowie deren Verwendung zur Diagnose, zum Screening mit hohem Durchsatz und zur Behandlung neuartiger Probleme
EP1100520B1 (de) * 1998-07-21 2004-09-22 Cytovia, Inc. Neue fluoreszensfarbstoffe und ihre anwendung in fluoreszensnachweisverfahren ganzer zellen für kaspasen, peptidasen, proteasen und andere enzyme sowie deren verwendung
US6667299B1 (en) * 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US6638977B1 (en) 1999-11-19 2003-10-28 Corvas International, Inc. Plasminogen activator inhibitor antagonists
US6677473B1 (en) 1999-11-19 2004-01-13 Corvas International Inc Plasminogen activator inhibitor antagonists
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
DE60017195T2 (de) 1999-12-31 2005-12-22 Encysive Pharmaceuticals, Inc., Houston Sulfonamide und ihre derivate, die die aktivität des endothelins modulieren
US7109315B2 (en) 2000-03-15 2006-09-19 Bruce J. Bryan Renilla reniformis fluorescent proteins, nucleic acids encoding the fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US6485707B2 (en) 2001-02-15 2002-11-26 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6596262B2 (en) 2001-02-15 2003-07-22 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
US6544497B2 (en) 2001-02-15 2003-04-08 Aeropharm Technology Incorporated Modulated release particles for aerosol delivery
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US20030129203A1 (en) * 2001-08-27 2003-07-10 Nautilus Biotech S.A. Mutant recombinant adeno-associated viruses
JP2005509616A (ja) * 2001-10-16 2005-04-14 センジェント・セラピューティクス・インク チロシンホスファターゼに対する有機硫黄阻害剤
AUPR868201A0 (en) * 2001-11-05 2001-11-29 Thorlock International Limited Q-factor switching method and apparatus for detecting nuclear quadrupole and nuclear magnetic resonance signals
WO2003060078A2 (en) * 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Heterocyclic modulators of nuclear receptors
EP1465869B1 (de) 2001-12-21 2013-05-15 Exelixis Patent Company LLC Modulatoren von lxr
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
US7582284B2 (en) 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US20030199594A1 (en) * 2002-04-23 2003-10-23 Rasik Shah Helium propellant composition for use with aerosols
US20040001801A1 (en) * 2002-05-23 2004-01-01 Corvas International, Inc. Conjugates activated by cell surface proteases and therapeutic uses thereof
DE60328496D1 (en) 2002-06-27 2009-09-03 Health Research Inc Fluorinierte chlorin und bacteriochlorin photosensitizer für fotodynamische therapie
EP2036908A3 (de) 2002-07-02 2009-05-13 Health Research, INC. Effiziente Synthese von Pyropheophorbid-A-Derivaten
CA2498319A1 (en) * 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20060020396A1 (en) * 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
US20050202438A1 (en) * 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
AP2005003319A0 (en) * 2002-11-19 2005-06-30 Achillion Pharmaceitucals Inc Substituted aryl thioureas and related compounds; inhibitors of viral replication
EP1575648A4 (de) * 2002-12-18 2007-07-04 Glaxo Group Ltd Arzneimittelabgabesystem mit belüftetem mundstück
US7871607B2 (en) * 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
KR20130135986A (ko) 2003-03-05 2013-12-11 할로자임, 아이엔씨 가용성 하이알우로니다제 당단백질 (ｓＨＡＳＥＧＰ), 이를 제조하는 방법, 용도 및 이를 포함하는 약학 조성물
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CA2525547C (en) * 2003-05-14 2012-07-03 Torreypines Therapeutics, Inc. Compounds and uses thereof in modulating amyloid beta
DE602004022668D1 (de) * 2003-06-03 2009-10-01 Novartis Ag 5-gliedrige heterocyclische p-38 inhibitoren
EP1911754B1 (de) 2003-08-13 2013-10-09 Takeda Pharmaceutical Company Limited Dipeptidyl-Peptidase-Hemmer
US7420000B2 (en) 2003-09-10 2008-09-02 University Of Southern California Amino phosphonate and amino bis-phosphonate derivatives
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
WO2005090370A1 (en) 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US8519158B2 (en) * 2004-03-12 2013-08-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
RU2371440C2 (ru) 2004-05-20 2009-10-27 Дзе Скриппс Рисёч Инститьют Стабилизация транстиретина
JP2008503490A (ja) * 2004-06-17 2008-02-07 センジェント・セラピューティクス・インコーポレイテッド チロシンホスファターゼの三置換窒素調節物質
WO2006017124A2 (en) * 2004-07-09 2006-02-16 Cengent Therapeutics, Inc. Oxygen/nitrogen heterocycle inhibitors of tyrosine phosphatases
WO2006017295A2 (en) 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
WO2006028970A1 (en) 2004-09-02 2006-03-16 Cengent Therapeutics, Inc. Derivatives of thiazole and thiadiazole inhibitors of tyrosine phosphatases
NZ554545A (en) 2004-09-17 2010-10-29 Whitehead Inst Of Biomedical R Compounds, compositions and methods of inhibiting alpha-synuclein toxicity
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8222257B2 (en) 2005-04-01 2012-07-17 The Regents Of The University Of California Phosphono-pent-2-en-1-yl nucleosides and analogs
CA2607806A1 (en) * 2005-05-04 2006-11-16 Nautilus Biotech, S.A. Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
AU2006259474B2 (en) 2005-06-17 2011-10-27 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US20100098640A1 (en) * 2005-06-20 2010-04-22 Cohen Seth M Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
WO2008051197A2 (en) * 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20070093443A1 (en) 2005-10-21 2007-04-26 Madison Edwin L Modified proteases that inhibit complement activation
WO2007076160A2 (en) * 2005-12-28 2007-07-05 Acidophil Llc C-10 carbamates of taxanes
EP2383271B1 (de) 2006-03-13 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Aminochinolone als GSK-3-Hemmer
WO2007110231A2 (en) * 2006-03-28 2007-10-04 Nautilus Biotech, S.A. MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
AU2007245129A1 (en) * 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
US8383388B2 (en) 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
JP5209625B2 (ja) 2006-08-28 2013-06-12 協和発酵キリン株式会社 アンタゴニストのヒトｌｉｇｈｔ特異的ヒトモノクローナル抗体
US7879846B2 (en) 2006-09-21 2011-02-01 Kyorin Pharmaceutical Co.., Ltd. Serine hydrolase inhibitors
EP2079696A2 (de) 2006-10-09 2009-07-22 Takeda San Diego, Inc. Kinase-inhibitoren
EP2223925A1 (de) 2006-10-09 2010-09-01 Takeda Pharmaceutical Company Limited Kinase-Inhibitoren
JP2010508307A (ja) 2006-10-31 2010-03-18 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
US20100137421A1 (en) * 2006-11-08 2010-06-03 Emmanuel Theodorakis Small molecule therapeutics, synthesis of analogues and derivatives and methods of use
WO2009070164A1 (en) 2007-11-28 2009-06-04 University Of Central Florida Vigor enhancement via administration of pyrimidine derivatives
KR101248252B1 (ko) 2006-11-28 2013-03-27 한올바이오파마주식회사 변형된 에리스로포이에틴 폴리펩티드와 이의 치료용 용도
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
CN101611008A (zh) * 2006-12-22 2009-12-23 恩希赛弗制药公司 C3a受体调节剂及其使用方法
ES2538082T3 (es) 2007-02-11 2015-06-17 Map Pharmaceuticals Inc Método de administración terapéutica de DHE para permitir el rápido alivio de migraña mientras que se minimiza el perfil de efectos secundarios
HRP20110713T1 (hr) * 2007-02-28 2011-11-30 Conatus Pharmaceuticals Postupci liječenja kroničnog virusnog hepatitisa c uz upotrebu ro 113-0830
CN101855228B (zh) * 2007-09-11 2012-10-24 杏林制药株式会社 作为gsk-3抑制剂的氰基氨基喹诺酮和四唑并氨基喹诺酮
BRPI0816814B1 (pt) 2007-09-12 2021-08-31 Kyorin Pharmaceutical Co. Ltd Composto, composição farmacêutica e uso de um composto
US20110201818A1 (en) 2007-09-25 2011-08-18 Takeda Pharmaceutical Company Limited Polo-like kinase inhibitors
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
WO2009066152A2 (en) 2007-11-21 2009-05-28 Pharmaxis Ltd. Haloallylamine inhibitors of ssao/vap-1 and uses therefor
BRPI0821090B8 (pt) 2007-12-21 2021-05-25 Ligand Pharm Inc moduladores seletivos de receptores de androgênio (sarms) e uso do mesmo
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
KR101647932B1 (ko) 2008-04-14 2016-08-11 할로자임, 아이엔씨 히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20110178070A1 (en) 2008-06-24 2011-07-21 Takeda Pharmaceutical Company Limited PI3K/mTOR INHIBITORS
ES2732453T3 (es) 2008-07-01 2019-11-22 Curemark Llc Métodos y composiciones para el tratamiento de síntomas de trastornos neurológicos y de salud mental
SI3037529T1 (sl) 2008-12-09 2019-06-28 Halozyme, Inc. Razširjeni topni polipeptidi PH20 in njihove uporabe
CN102300989B (zh) 2009-01-06 2015-12-09 柯尔朗恩有限责任公司 用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
EP2373693A4 (de) 2009-01-06 2012-04-25 Curelon Llc Zusammensetzungen und verfahren zur behandlung bzw. prävention von mundinfektionen durch e.coli
JP5649589B2 (ja) * 2009-03-06 2015-01-07 ハロザイム インコーポレイテッド マトリックスメタロプロテアーゼ１の温度感受性突然変異体およびその使用
MX2011009414A (es) * 2009-03-11 2011-10-19 Kyorin Seiyaku Kk 7-cicloalquiloaminoquinolonas como inhibidores de gsk-3.
US8669249B2 (en) 2009-03-27 2014-03-11 Takeda Pharmaceutical Company Limited Poly (ADP-ribose) polymerase (PARP) inhibitors
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
JP5715625B2 (ja) 2009-07-30 2015-05-07 武田薬品工業株式会社 ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
EP2499282B1 (de) 2009-11-09 2015-04-22 NeuroGenetic Pharmaceuticals, Inc. Gamma-sekretase-modulierende verbindungen, verfahren zu ihrer identifikation und verwendungen dafür
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
IN2012DN04858A (de) * 2009-12-23 2015-09-25 Map Pharmaceuticals Inc
CA2784799C (en) 2009-12-30 2014-06-10 Shanghai Fochon Pharmaceutical Co Ltd Certain dipeptidyl peptidase inhibtors
EP2531501B1 (de) 2010-02-03 2013-11-20 Takeda Pharmaceutical Company Limited Aptoptosesignalregelnde kinase-1-hemmer
US9403815B2 (en) 2010-06-24 2016-08-02 The Regents Of The University Of California Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
CN103619348B (zh) 2011-04-21 2016-10-26 柯尔马克有限责任公司 用于治疗神经精神障碍的化合物
WO2012177962A1 (en) 2011-06-23 2012-12-27 Map Pharmaceuticals, Inc. Novel fluoroergoline analogs
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
EP2793580A4 (de) 2011-12-19 2015-05-20 Map Pharmaceuticals Inc Neuartige isoergolinderivate
SG11201403433PA (en) 2011-12-21 2014-07-30 Map Pharmaceuticals Inc Novel neuromodulatory compounds
ES2609582T3 (es) 2011-12-30 2017-04-21 Halozyme, Inc. Variantes de polipéptidos de PH20, formulaciones y usos de los mismos
WO2013134047A2 (en) 2012-03-07 2013-09-12 The Mclean Hospital Corporation Aminoquinoline derivatives and uses thereof
BR112014024848A2 (pt) 2012-04-04 2017-07-11 Halozyme Inc terapia de combinação com um agente antihialuronano e um taxano direcionamento ao tumor
DK2844637T5 (en) 2012-05-02 2018-08-13 Boehringer Ingelheim Int SUBSTITUTED 3-HALOALLYLAMINE INHIBITORS BY SSAO AND USES THEREOF
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP2861562B1 (de) 2012-06-14 2018-05-09 Mayo Foundation For Medical Education And Research Pyrazolderivate als hemmer von stat3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
AU2013361340A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. Novel methysergide derivatives
US20150196625A9 (en) 2013-01-07 2015-07-16 Rudolph D. Paladini Metal Sensitive Mutants of Matrix Metalloproteases and uses thereof
CN105163732B (zh) 2013-02-22 2020-01-07 南加州大学 用于治疗眼科疾病和病症的方法
US9938263B2 (en) 2013-03-12 2018-04-10 The General Hospital Corporation Gamma-secretase modulators
CA2911376C (en) 2013-03-15 2021-03-30 University Of Southern California Phenyl(sulfonylcarbamate) derivatives and pharmaceutical compositions thereof for the treatment of angiotensin-related diseases
WO2014197849A2 (en) 2013-06-06 2014-12-11 Igenica Biotherapeutics, Inc. Anti-c10orf54 antibodies and uses thereof
TW201534726A (zh) 2013-07-03 2015-09-16 Halozyme Inc 熱穩定ｐｈ２０玻尿酸酶變異體及其用途
EP3094323A4 (de) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Verfahren und zusammensetzungen zur modulierung von hormonspiegeln
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20170100448A1 (en) 2014-05-12 2017-04-13 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitors
MA47849A (fr) 2014-05-28 2020-01-29 Agenus Inc Anticorps anti-gitr et leurs procédés d'utilisation
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
EA201700181A1 (ru) 2014-10-14 2017-09-29 Галозим, Инк. Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
WO2016065264A1 (en) 2014-10-24 2016-04-28 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
EP3212633B1 (de) 2014-10-31 2019-12-04 The General Hospital Corporation Wirksame gammasekretasemodulatoren
DK3229838T3 (da) 2014-12-11 2020-10-19 Pf Medicament Anti-C10orf54-antistoffer og anvendelser deraf
EP3237450B1 (de) 2014-12-22 2021-03-03 The Rockefeller University Anti-mertk-antikörper und verwendungen davon
CN113149982A (zh) 2015-01-20 2021-07-23 Xoc制药股份有限公司 麦角灵化合物及其用途
CN107405346A (zh) 2015-01-20 2017-11-28 Xoc制药股份有限公司 异麦角灵化合物及其用途
FI3265123T3 (fi) 2015-03-03 2023-01-31 Vasta-aineita, käyttöjä & menetelmiä
EP3289104B1 (de) 2015-04-29 2020-11-04 New York University Verfahren zur behandlung von hochwertigen gliomen
KR20230028478A (ko) 2015-05-29 2023-02-28 아게누스 인코포레이티드 항-ctla-4 항체 및 이의 사용 방법
HRP20211976T1 (hr) 2015-08-17 2022-03-18 Kura Oncology, Inc. Postupci liječenja bolesnika od raka inhibitorima farnezil transferaze
KR20220131277A (ko) 2015-09-01 2022-09-27 아게누스 인코포레이티드 항-pd-1 항체 및 이를 이용하는 방법
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
EP4455145A3 (de) 2015-12-02 2025-03-12 Astraea Therapeutics, LLC Piperidinyl-nociceptin-rezeptorverbindungen
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
AU2016381974A1 (en) 2015-12-31 2018-07-12 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
KR20180095094A (ko) 2016-01-08 2018-08-24 셀진 코포레이션 암을 치료하기 위한 방법 및 치료요법에 대한 임상 감수성의 예측변수로서 바이오마커의 용도
MX385964B (es) 2016-01-08 2025-03-18 Celgene Corp Formas sólidas de 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il) metil)-2,2-difluoroacetamida y sus composiciones farmacéuticas y usos.
HUE051231T2 (hu) 2016-01-08 2021-03-01 Celgene Corp Antiproliferatív vegyületek, és ezek gyógyszerészeti összetételei és alkalmazásai
US10960013B2 (en) 2016-03-04 2021-03-30 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
JP2019510085A (ja) 2016-03-08 2019-04-11 ロス ガトス ファーマスーティカルズ， インク．Ｌｏｓ Ｇａｔｏｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 癌治療のためのナノ粒子ならびに方法および化合物
WO2017156183A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Camptothecin derivatives and uses thereof
US10047077B2 (en) 2016-04-13 2018-08-14 Skyline Antiinfectives, Inc. Deuterated O-sulfated beta-lactam hydroxamic acids and deuterated N-sulfated beta-lactams
US20190119758A1 (en) 2016-04-22 2019-04-25 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
ES2939373T3 (es) 2016-05-13 2023-04-21 Pasteur Institut Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
TWI781934B (zh) 2016-05-27 2022-11-01 美商艾吉納斯公司 抗-tim-3抗體及其使用方法
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
US10919904B2 (en) 2016-08-17 2021-02-16 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
MA46529A (fr) 2016-10-11 2019-08-21 Agenus Inc Anticorps anti-lag-3 et leurs procédés d'utilisation
EP3838275A1 (de) 2016-11-03 2021-06-23 Kura Oncology, Inc. Farnesyltransferase-inhibitoren zur verwendung bei der behandlung von krebs
EP3534947A1 (de) 2016-11-03 2019-09-11 Kymab Limited Antikörper, kombinationen mit antikörpern, biomarker, verwendungen und verfahren
US11332521B2 (en) 2016-11-07 2022-05-17 Neuracle Science Co., Ltd. Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
JP6992068B2 (ja) 2016-12-07 2022-02-03 アジェナス インコーポレイテッド 抗ｃｔｌａ－４抗体およびそれらの使用方法
PE20190921A1 (es) 2016-12-07 2019-06-26 Agenus Inc Anticuerpos y metodos de su utilizacion
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
CA3053795A1 (en) 2017-02-21 2018-08-30 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3609528A4 (de) 2017-04-10 2020-12-23 Curemark, LLC Zusammensetzungen zur suchtbehandlung
TW202500588A (zh) 2017-04-13 2025-01-01 美商艾吉納斯公司 抗ｃｄ１３７抗體及其使用方法
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
MA50957A (fr) 2017-05-01 2020-10-14 Agenus Inc Anticorps anti-tigit et leurs méthodes d'utilisation
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
CA3064274A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
AU2018290281B2 (en) 2017-06-22 2021-12-16 Vertex Pharmaceuticals Incorporated Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
US10323289B2 (en) 2017-06-26 2019-06-18 Institut Pasteur Treatments to eliminate HIV reservoirs and reduce viral load
EP3645040A4 (de) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd Verwendung von anti-fam19a5-antikörpern zur krebsbehandlung
EP3645039A4 (de) 2017-06-27 2021-05-05 Neuracle Science Co., Ltd Verwendung von anti-fam19a5-antikörpern zur behandlung von fibrose
CN111315774B (zh) 2017-06-27 2023-12-22 纽洛可科学有限公司 抗fam19a5抗体及其用途
CN110972463B (zh) 2017-06-27 2024-05-28 纽洛可科学有限公司 抗序列相似家族19成员a5抗体在治疗青光眼中的用途
JP7097438B2 (ja) 2017-07-11 2022-07-07 アクティム・セラピューティクス・インコーポレイテッド 遺伝子操作された免疫刺激性細菌菌株およびその使用
CA3071854A1 (en) 2017-08-07 2019-02-14 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP4265257A1 (de) 2017-09-01 2023-10-25 East Carolina University Kombination eines prostaglandin-ethanolamids der j-serie und eines checkpoint-inhibitors zur verwendung bei der behandlung von krebs
WO2019069229A1 (en) 2017-10-02 2019-04-11 Neuracle Science Co., Ltd. USE OF ANTIBODIES DIRECTED AGAINST A SIMILARITY FAMILY OF SEQUENCE 19, ELEMENT A5, FOR THE TREATMENT AND DIAGNOSIS OF MOOD DISORDERS
KR20200074975A (ko) 2017-10-31 2020-06-25 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
US20190216751A1 (en) 2017-11-15 2019-07-18 California State University Northridge Compositions and Methods for the Treatment and Prevention of Cancer
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
CN112424223B (zh) 2018-04-24 2024-12-17 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体在治疗神经性疼痛中的用途
CN112074605B (zh) 2018-05-08 2024-11-22 纽洛可科学有限公司 抗fam19a5抗体的腺相关病毒（aav）递送
EP3790898A4 (de) 2018-05-10 2022-03-02 Neuracle Science Co., Ltd Anti-familie mit sequenzähnlichkeit 19, element a5-antikörper und verfahren zur verwendung davon
WO2019222435A1 (en) 2018-05-16 2019-11-21 Halozyme, Inc. Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
CA3105352A1 (en) 2018-06-29 2020-01-02 Histogen, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
KR20240067973A (ko) 2018-07-11 2024-05-17 액팀 테라퓨틱스, 인코퍼레이티드 조작된 면역자극성 박테리아 균주 및 이의 용도
IL280199B2 (en) 2018-07-20 2025-08-01 Pf Medicament Receptor for vista
EP3844276A2 (de) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Manipulierte immunstimulierende bakterienstämme und verwendungen davon
EP3860713A2 (de) 2018-10-03 2021-08-11 Staten Biotechnology B.V. Antikörper spezifisch für menschliches und cynomolgus-apoc3 und verfahren zur verwendung davon
EP3867272A4 (de) 2018-10-16 2022-08-03 Neuracle Science Co., Ltd Verwendung von anti-fam19a5-antikörpern
EP3873469A2 (de) 2018-11-01 2021-09-08 Kura Oncology, Inc. Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren
WO2020102728A1 (en) 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
WO2020118042A1 (en) 2018-12-05 2020-06-11 Jacobs Wagner Christine Borrelia burgdorferi peptidoglycan as a diagnostic and target for therapeutic intervention of lyme disease-related pathologies
JP7407461B2 (ja) 2018-12-19 2024-01-04 シャイ・セラピューティクス・エルエルシー がん、炎症性疾患、ｒａｓ病、及び線維性疾患の処置のためのｒａｓスーパーファミリーと相互作用する化合物
WO2020128033A1 (en) 2018-12-20 2020-06-25 Institut Pasteur Cellular metabolism of hiv-1 reservoir seeding in cd4+ t cells
CA3124616A1 (en) 2018-12-21 2020-06-25 Kura Oncology, Inc. Therapies for squamous cell carcinomas
KR102757347B1 (ko) 2018-12-27 2025-01-23 주식회사 뉴라클사이언스 죽상경화증을 치료하기 위한 항-fam19a5 항체의 사용
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
MY205567A (en) 2018-12-28 2024-10-26 Vertex Pharma Modified urokinase-type plasminogen activator polypeptides and methods of use
EP3906260A4 (de) 2019-01-02 2022-08-31 Neuracle Science Co., Ltd Anti-familie mit sequenzähnlichkeit 19, element a5-antikörper und verfahren zur verwendung davon
EP3921038A1 (de) 2019-02-06 2021-12-15 Dice Alpha, Inc. Il-17a modulators and uses thereof
FI3930847T3 (fi) 2019-02-26 2024-04-23 Inspirna Inc Korkea-affiinisia anti-MERTK-vasta-aineita ja niiden käyttöjä
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
WO2020176809A1 (en) 2019-02-27 2020-09-03 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US20220142983A1 (en) 2019-03-01 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
IL286149B2 (en) 2019-03-07 2025-02-01 Histogen Inc CASPASE INHIBITORS AND METHODS OF USING THEM
TW202108170A (zh) 2019-03-15 2021-03-01 美商庫拉腫瘤技術股份有限公司 以法呢基轉移酶(farnesyltransferase)抑制劑治療癌症患者之方法
EP3946338B1 (de) 2019-03-29 2025-06-18 Kura Oncology, Inc. Verfahren zur behandlung von plattenepithelkarzinomen mit farnesyltransferase-inhibitoren
WO2020205387A1 (en) 2019-04-01 2020-10-08 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
EP3956309A4 (de) 2019-04-19 2023-06-07 Ligand Pharmaceuticals Inc. Kristalline formen und verfahren zur herstellung kristalliner formen einer verbindung
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
CN114222802B (zh) 2019-05-20 2025-07-11 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
CN119752217A (zh) 2019-05-20 2025-04-04 尼尔瓦纳科学股份有限公司 窄发射染料、包含其的组合物以及制备和使用其的方法
CR20220076A (es) 2019-08-30 2022-06-24 Agenus Inc Anticuerpos anti-cd96 y sus métodos de uso
MX2022003166A (es) 2019-09-16 2022-06-29 Dice Alpha Inc Moduladores de il-17a y usos de los mismos.
MX2022005705A (es) 2019-11-12 2022-08-16 Actym Therapeutics Inc Plataformas de suministro bacteriano inmunomoduladoras y su uso para el suministro de productos terapéuticos.
US20230057939A1 (en) 2020-01-13 2023-02-23 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and a bispecific antibody
US20230210952A1 (en) 2020-02-05 2023-07-06 Washington University Method of treating a solid tumor with a combination of an il-7 protein and car-bearing immune cells
EP4168414A1 (de) 2020-06-18 2023-04-26 Shy Therapeutics LLC Substituierte thienopyrimidine zur interaktion mit der ras-superfamilie zur behandlung von krebs, entzündlichen erkrankungen, rasopathien und fibrotischen erkrankungen
US12024521B2 (en) 2020-06-30 2024-07-02 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
MX2023001782A (es) 2020-08-12 2023-05-22 Actym Therapeutics Inc Vacunas, productos terapéuticos y plataformas de administración de arn a base de bacterias inmunoestimuladoras.
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
EP4232070A1 (de) 2020-10-26 2023-08-30 NeoImmuneTech, Inc. Verfahren zur induktion von stammzellenmobilisierung
EP4236989A1 (de) 2020-11-02 2023-09-06 NeoImmuneTech, Inc. Verwendung von interleukin-7 zur behandlung des coronavirus
EP4240408A1 (de) 2020-11-05 2023-09-13 Neoimmunetech, Inc. Verfahren zur behandlung eines tumors mit einer kombination aus einem il-7-protein und einem nukleotidimpfstoff
US20240309015A1 (en) 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
EP4284377A1 (de) 2021-01-27 2023-12-06 Shy Therapeutics LLC Verfahren zur behandlung von fibrotischen erkrankungen
KR20230169979A (ko) 2021-03-10 2023-12-18 다이스 몰레큘스 에스브이, 인크. 알파 v 베타 6 및 알파 v 베타 1 인테그린 억제제 및 그의 용도
WO2022226166A1 (en) 2021-04-22 2022-10-27 Protego Biopharma, Inc. Spirocyclic imidazolidinones and imidazolidinediones for treatment of light chain amyloidosis
EP4347568A1 (de) 2021-05-27 2024-04-10 Protego Biopharma, Inc. Heteroaryldiamid-ire1/xbp1s-aktivatoren
JP2024522213A (ja) 2021-06-14 2024-06-11 アルジェニクス ビーブイ 抗ｉｌ－９抗体及びその使用方法
JP2024539134A (ja) 2021-10-22 2024-10-28 プロセッタ バイオサイエンシズ， インク． 新規な宿主標的汎呼吸器抗ウイルス小分子治療薬
KR20240115979A (ko) 2021-11-08 2024-07-26 프로젠토스 테라퓨틱스, 인크. 혈소판-유래 성장 인자 수용체(pdgfr) 알파 억제제 및 이의 용도
US20250099542A1 (en) 2021-12-30 2025-03-27 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
WO2023129577A1 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
JP2025507621A (ja) 2022-03-02 2025-03-21 ミトパワー， インク． ニコチン酸及びリボースから誘導体化した新規プロドラッグ
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
AR129053A1 (es) 2022-04-14 2024-07-10 Bristol Myers Squibb Co Nuevos compuestos gspt1 y métodos de uso de los nuevos compuestos
WO2023198757A1 (en) 2022-04-14 2023-10-19 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Alpha-1-antitrypsin for treating paramyxoviridae or orthomyxoviridae infections
CA3268194A1 (en) 2022-10-21 2024-04-25 Diagonal Therapeutics Inc. HETEROMERIC AGONIST ANTIBODIES DIRECTED AGAINST IL-18 RECEPTOR
US20240174695A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Bicyclic Heteroaryl Compounds
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
EP4608838A1 (de) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocyclus mit pyridonverbindungen
JP2026504619A (ja) 2022-11-07 2026-02-06 ネオイミューンテック， インコーポレイテッド 非メチル化ｍｇｍｔプロモーターを含む腫瘍を治療する方法
WO2024118810A1 (en) 2022-11-30 2024-06-06 Protego Biopharma, Inc. Cyclic pyrazole diamide ire1/xbp1s activators
EP4626864A1 (de) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Lineare heteroaryldiamid-ire1/xbp1s-aktivatoren
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
JP2026509512A (ja) 2023-03-17 2026-03-19 オキシトープ ファーマ ベー．フェー． 抗ホスホコリン抗体およびその使用方法
US20240383990A1 (en) 2023-04-07 2024-11-21 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies
CN121127500A (zh) 2023-04-07 2025-12-12 达科纳治疗有限公司 针对激活素a受体样1型(alk1)的双特异性激动性抗体
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
CN121263415A (zh) 2023-05-09 2026-01-02 普罗根托斯治疗公司 杂环化合物及其用途
AU2024276812A1 (en) 2023-05-19 2025-11-06 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
KR20260033048A (ko) 2023-07-03 2026-03-10 네오이뮨텍, 인코퍼레이티드 이종이합체 fc 분자 및 이의 용도
WO2025049818A1 (en) 2023-08-29 2025-03-06 Enosi Therapeutics Corporation Tnfr1 antagonists lacking agonist activity and uses thereof
WO2025046298A2 (en) 2023-09-01 2025-03-06 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
TW202530223A (zh) 2023-09-27 2025-08-01 美商艾索司特瑞克斯公司 Ｍｙｓｔ抑制劑
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
AU2024366926A1 (en) 2023-10-23 2026-03-12 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation
WO2025255341A1 (en) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Tetrahydrofuranyl ire1/xbp1s activators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2849460A (en) * 1953-11-17 1958-08-26 Olin Mathieson Purification of steroids
BE556587A (de) * 1957-01-31 1957-04-11
GB1047518A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
US3320125A (en) * 1964-04-28 1967-05-16 Merck & Co Inc Inhalation aerosol composition
US3282791A (en) * 1965-08-17 1966-11-01 Merck & Co Inc Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
NL6810103A (de) * 1967-07-31 1969-02-04
GB1253831A (en) * 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
US4119548A (en) * 1977-10-28 1978-10-10 Mobil Oil Corporation Reaction product of nickel thiobis(alkylphenolate) and thiobis(alkylphenol) and organic compositions containing the same

Also Published As

Publication number Publication date
IL42038A (en) 1976-11-30
NO140303C (no) 1979-08-08
DE2320111A1 (de) 1973-10-31
DK134923B (da) 1977-02-14
FR2182981A1 (de) 1973-12-14
ZA732713B (en) 1974-11-27
CA994753A (en) 1976-08-10
US4414209A (en) 1983-11-08
DK134923C (de) 1977-07-04
FI53067B (de) 1977-10-31
DE2320111C2 (de) 1986-12-04
NL7305438A (de) 1973-10-23
AU5466073A (en) 1974-10-24
ES413911A1 (es) 1976-06-16
IE37541B1 (en) 1977-08-17
LU67462A1 (de) 1973-07-05
JPS531814B2 (de) 1978-01-23
JPS4919014A (de) 1974-02-20
GB1429184A (en) 1976-03-24
IE37541L (en) 1973-10-20
AR196524A1 (es) 1974-02-06
BE798458A (fr) 1973-10-19
YU108673A (en) 1982-06-30
PH13620A (en) 1980-08-07
FR2182981B1 (de) 1976-12-31
IL42038A0 (en) 1973-06-29
YU39602B (en) 1985-03-20
HU171209B (hu) 1977-12-28
FI53067C (de) 1978-02-10
US4364923A (en) 1982-12-21
SE399642B (sv) 1978-02-27
ATA352973A (de) 1978-06-15
AU471577B2 (en) 1976-04-29
NO140303B (no) 1979-04-30
NL157797B (nl) 1978-09-15

Similar Documents

Publication Publication Date Title
AT348115B (de) Verfahren zur umwandlung eines anti- inflammatorisch wirkenden steroids
AT328630B (de) Verfahren zur herstellung neuer steroide
AT260440B (de) Verfahren zur Herstellung neuer Steroide
AT341637B (de) Verfahren zur losungsmittelentparaffinierung
AT307344B (de) Verfahren zur Bodenprobenentnahme und Gerät zur Durchführung dieses Verfahrens
AT336811B (de) Verfahren zur herstellung von steroidspirolactonen
AT298697B (de) Verfahren zur Herstellung neuer Steroide
AT338201B (de) Verfahren zur gewinnung von neuer steroid-delta-isomerase
NL177327C (nl) Werkwijze ter bereiding van ergosterol of esters daarvan.
CA938898A (en) Apparatus and method of repairing tube structures
AT314098B (de) Verfahren zur Äthinylierung von 17-Ketosteroiden
AT315396B (de) Verfahren zur Herstellung neuer Steroide
AT330966B (de) Verfahren zur herstellung neuer steroide
AT313492B (de) Verfahren zur Herstellung neuer Steroidverbindungen
ATA906971A (de) Verfahren zur herstellung neuer 3-oximino-17alfa-propadienyl-substituierter steroide
AT325787B (de) Verfahren zur herstellung von 17beta- lactonen von 14beta-hydroxysteroiden
ATA135872A (de) Verfahren zur herstellung neuer steroide
AT359212B (de) Verfahren zur herstellung neuer pharma- zeutisch aktiver steroide
AT325788B (de) Verfahren zur herstellung von 18-methylensteroiden
CH499511A (de) Verfahren zur Herstellung eines 9B,10a-Steroids
ATA312673A (de) Verfahren zur herstellung neuer steroide
AT329779B (de) Verfahren zur herstellung neuer steroiden
CH553766A (de) Verfahren zur herstellung neuer steroide.
CH552579A (de) Verfahren zur herstellung neuer steroide.
ATA353471A (de) Verfahren zur herstellung substituierter steroide

Legal Events

Date Code Title Description
ELJ Ceased due to non-payment of the annual fee
ELA Expired due to lapse of time